



## Clinical trial results:

### Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors

#### Summary

|                          |                   |
|--------------------------|-------------------|
| EudraCT number           | 2018-000265-37    |
| Trial protocol           | ES                |
| Global end of trial date | 08 September 2020 |

#### Results information

|                                |   |
|--------------------------------|---|
| Result version number          | v2 (current)  |
| This version publication date  | 24 November 2021  |
| First version publication date | 19 September 2021   |
| Version creation reason        | <ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Errors in time frame were corrected |

#### Trial information

##### Trial identification

|                       |             |
|-----------------------|-------------|
| Sponsor protocol code | BGB-900-101 |
|-----------------------|-------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT03379259 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | BeiGene, Ltd  |
| Sponsor organisation address | BeiGene, Ltd., c/o BeiGene USA, Inc. 2955 Campus Drive, Suite 200 , San Mateo, California, United States, 94403 |
| Public contact               | BeiGene DDT Call Center, BeiGene Ltd., 1-877 828-5568, clinicaltrials@beigene.com                               |
| Scientific contact           | BeiGene DDT Call Center, BeiGene Ltd., 1-877 828-5568, clinicaltrials@beigene.com                               |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                   |
|--|-------------------|
| Analysis stage                                       | Final             |
| Date of interim/final analysis                       | 04 November 2020  |
| Is this the analysis of the primary completion data? | No                |
| Global end of trial reached?                         | Yes               |
| Global end of trial date                             | 08 September 2020 |
| Was the trial ended prematurely?                     | Yes               |

Notes:

## General information about the trial

Main objective of the trial:

1) For Phase 1:

- To assess the safety and tolerability of BGB-A333 alone and in combination with tislelizumab in patients with advanced solid tumors
- To determine the MTD, if any, and RP2D for BGB-A333 alone and in combination with tislelizumab

2) For Phase 2: To assess ORR per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 of BGB-A333 alone and in combination with tislelizumab in patients with selected tumor types

Protection of trial subjects:

This trial was designed and monitored in accordance with Sponsor procedures, which comply with the ethical principles of GCP as required by the major regulatory authorities, and in accordance with the Declaration of Helsinki. The IEC/IRB-approved ICF was signed and dated by the subject or the subject's legally authorized representative before his or her participation in the study. A copy of each signed ICF was provided to the subject or the subject's legally authorized representative. All signed and dated ICFs were retained in each patient's study file or in the site file. For any updated or revised ICFs, written informed consent was obtained using the IEC/IRB-approved updated/revised ICFs for continued participation in the study.

Background therapy: -

Evidence for comparator: -

|   |                  |
|---|------------------|
| Actual start date of recruitment                          | 27 November 2017 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | No               |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                |
|--------------------------------------|----------------|
| Country: Number of subjects enrolled | Australia: 28  |
| Country: Number of subjects enrolled | New Zealand: 4 |
| Country: Number of subjects enrolled | Spain: 7       |
| Worldwide total number of subjects   | 39             |
| EEA total number of subjects         | 7              |

Notes:

### Subjects enrolled per age group

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

|  |    |
|--|----|
| Newborns (0-27 days)                     | 0  |
| Infants and toddlers (28 days-23 months) | 0  |
| Children (2-11 years)                    | 0  |
| Adolescents (12-17 years)                | 0  |
| Adults (18-64 years)                     | 16 |
| From 65 to 84 years                      | 23 |
| 85 years and over                        | 0  |

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted at 8 study centers in Australia, 1 study center in New Zealand, and 3 study centers in Spain.

### Pre-assignment

Screening details:

A total of 39 patients were enrolled in the study and all received  $\geq 1$  dose of study drug.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Non-randomised - controlled    |
| Blinding used                | Not blinded                    |

### Arms

|                              |                           |
|------------------------------|---------------------------|
| Are arms mutually exclusive? | Yes                       |
| <b>Arm title</b>             | Phase 1A: BGB-A333 450 mg |

Arm description:

BGB-A333 450 mg, intravenously, every 3 weeks

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | BGB-A333              |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Dose ranging from 450 mg to 1800 mg, administered every three weeks

|                  |                           |
|------------------|---------------------------|
| <b>Arm title</b> | Phase 1A: BGB-A333 900 mg |
|------------------|---------------------------|

Arm description:

BGB-A333 900 mg, intravenously, every 3 weeks

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | BGB-A333              |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Dose ranging from 450 mg to 1800 mg, administered every three weeks

|                  |                            |
|------------------|----------------------------|
| <b>Arm title</b> | Phase 1A: BGB-A333 1350 mg |
|------------------|----------------------------|

Arm description:

BGB-A333 1350 mg, intravenously, every 3 weeks

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | BGB-A333              |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Dose ranging from 450 mg to 1800 mg, administered every three weeks

|                  |                            |
|------------------|----------------------------|
| <b>Arm title</b> | Phase 1A: BGB-A333 1800 mg |
|------------------|----------------------------|

Arm description:

BGB-A333 1800 mg, intravenously, every 3 weeks

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | BGB-A333              |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Dose ranging from 450 mg to 1800 mg, administered every three weeks

|                  |  |
|------------------|--|
| <b>Arm title</b> | Phase 1B: BGB-A333 1350 mg + Tislelizumab 200 mg |
|------------------|--|

Arm description:

BGB-A333 1350 mg, intravenously, + Tislelizumab 200 mg, intravenously, every 3 weeks

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | BGB-A333              |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Dose ranging from 450 mg to 1800 mg, administered every three weeks

|  |                       |
|--|-----------------------|
| Investigational medicinal product name | BGB-A317              |
| Investigational medicinal product code |                       |
| Other name                             | Tislelizumab          |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Tislelizumab 200 mg, intravenously, every 3 weeks

|                  |  |
|------------------|--|
| <b>Arm title</b> | Phase 2B: BGB-A333 1350 mg + Tislelizumab 200 mg |
|------------------|--|

Arm description:

BGB-A333 1350 mg, intravenously, + Tislelizumab 200 mg, intravenously, every 3 weeks (Urothelial Carcinoma Cohort)

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | BGB-A333              |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Dose ranging from 450 mg to 1800 mg, administered every three weeks

|  |                       |
|--|-----------------------|
| Investigational medicinal product name | BGB-A317              |
| Investigational medicinal product code |                       |
| Other name                             | Tislelizumab          |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Tislelizumab 200 mg, intravenously, every 3 weeks

| <b>Number of subjects in period 1</b> | Phase 1A: BGB-A333 450 mg | Phase 1A: BGB-A333 900 mg | Phase 1A: BGB-A333 1350 mg |
|---------------------------------------|---------------------------|---------------------------|----------------------------|
| Started                               | 3                         | 3                         | 6                          |
| Completed                             | 2                         | 2                         | 3                          |
| Not completed                         | 1                         | 1                         | 3                          |
| Consent withdrawn by subject          | -                         | -                         | 1                          |
| Disease progression                   | -                         | -                         | -                          |
| Death                                 | -                         | 1                         | 2                          |
| Study terminated by sponsor           | -                         | -                         | -                          |
| Deteriorating condition               | -                         | -                         | -                          |
| Commenced new anti-cancer therapy     | 1                         | -                         | -                          |
| Study terminated by sponsor           | -                         | -                         | -                          |
| Lost to follow-up                     | -                         | -                         | -                          |

| <b>Number of subjects in period 1</b> | Phase 1A: BGB-A333 1800 mg | Phase 1B: BGB-A333 1350 mg + Tislelizumab 200 mg | Phase 2B: BGB-A333 1350 mg + Tislelizumab 200 mg |
|---------------------------------------|----------------------------|--|--|
|                                       |                            |  |  |
| Started                               | 3                          | 12   | 12   |
| Completed                             | 0                          | 3  | 5  |
| Not completed                         | 3                          | 9  | 7  |
| Consent withdrawn by subject          | -                          | 2  | -  |
| Disease progression                   | 1                          | -  | 1  |
| Death                                 | 1                          | 4  | 2  |
| Study terminated by sponsor           | 1                          | -  | 4  |
| Deteriorating condition               | -                          | 1  | -  |
| Commenced new anti-cancer therapy     | -                          | -  | -  |
| Study terminated by sponsor           | -                          | 1  | -  |
| Lost to follow-up                     | -                          | 1  | -  |

## Baseline characteristics

### Reporting groups

|  |  |
|--|--|
| Reporting group title  | Phase 1A: BGB-A333 450 mg                        |
| Reporting group description:<br>BGB-A333 450 mg, intravenously, every 3 weeks  |  |
| Reporting group title  | Phase 1A: BGB-A333 900 mg                        |
| Reporting group description:<br>BGB-A333 900 mg, intravenously, every 3 weeks  |  |
| Reporting group title  | Phase 1A: BGB-A333 1350 mg                       |
| Reporting group description:<br>BGB-A333 1350 mg, intravenously, every 3 weeks   |  |
| Reporting group title  | Phase 1A: BGB-A333 1800 mg                       |
| Reporting group description:<br>BGB-A333 1800 mg, intravenously, every 3 weeks   |  |
| Reporting group title  | Phase 1B: BGB-A333 1350 mg + Tislelizumab 200 mg |
| Reporting group description:<br>BGB-A333 1350 mg, intravenously, + Tislelizumab 200 mg, intravenously, every 3 weeks                               |  |
| Reporting group title  | Phase 2B: BGB-A333 1350 mg + Tislelizumab 200 mg |
| Reporting group description:<br>BGB-A333 1350 mg, intravenously, + Tislelizumab 200 mg, intravenously, every 3 weeks (Urothelial Carcinoma Cohort) |  |

| Reporting group values  | Phase 1A: BGB-A333 450 mg | Phase 1A: BGB-A333 900 mg | Phase 1A: BGB-A333 1350 mg |
|---|---------------------------|---------------------------|----------------------------|
| Number of subjects  | 3                         | 3                         | 6                          |
| Age categorical<br>Units: Subjects  |                           |                           |                            |
| In utero<br>Preterm newborn infants (gestational age < 37 wks)<br>Newborns (0-27 days)<br>Infants and toddlers (28 days-23 months)<br>Children (2-11 years)<br>Adolescents (12-17 years)<br>Adults (18-64 years)<br>From 65-84 years<br>85 years and over |                           |                           |                            |
| Age continuous<br>Units: years  |                           |                           |                            |
| arithmetic mean   | 56.0                      | 60.3                      | 58.8                       |
| standard deviation  | ± 7.21                    | ± 11.24                   | ± 14.52                    |
| Gender categorical<br>Units: Subjects   |                           |                           |                            |
| Female  | 2                         | 2                         | 4                          |
| Male  | 1                         | 1                         | 2                          |
| PD-L1 Status<br>Units: Subjects   |                           |                           |                            |
| Positive  | 0                         | 2                         | 2                          |

|          |   |   |   |
|----------|---|---|---|
| Negative | 2 | 1 | 3 |
| Missing  | 1 | 0 | 1 |

| Reporting group values  | Phase 1A: BGB-A333 1800 mg | Phase 1B: BGB-A333 1350 mg + Tislelizumab 200 mg | Phase 2B: BGB-A333 1350 mg + Tislelizumab 200 mg |
|---|----------------------------|--|--|
| Number of subjects  | 3                          | 12   | 12   |
| Age categorical<br>Units: Subjects  |                            |  |  |
| In utero<br>Preterm newborn infants (gestational age < 37 wks)<br>Newborns (0-27 days)<br>Infants and toddlers (28 days-23 months)<br>Children (2-11 years)<br>Adolescents (12-17 years)<br>Adults (18-64 years)<br>From 65-84 years<br>85 years and over |                            |  |  |
| Age continuous<br>Units: years  |                            |  |  |
| arithmetic mean   | 58.0                       | 65.3   | 67.5   |
| standard deviation  | ± 16.52                    | ± 10.85  | ± 8.52   |
| Gender categorical<br>Units: Subjects   |                            |  |  |
| Female  | 2                          | 7  | 1  |
| Male  | 1                          | 5  | 11   |
| PD-L1 Status<br>Units: Subjects   |                            |  |  |
| Positive  | 1                          | 4  | 6  |
| Negative  | 2                          | 7  | 6  |
| Missing   | 0                          | 1  | 0  |

| Reporting group values  | Total                                |  |  |
|---|--------------------------------------|--|--|
| Number of subjects  | 39                                   |  |  |
| Age categorical<br>Units: Subjects  |                                      |  |  |
| In utero<br>Preterm newborn infants (gestational age < 37 wks)<br>Newborns (0-27 days)<br>Infants and toddlers (28 days-23 months)<br>Children (2-11 years)<br>Adolescents (12-17 years)<br>Adults (18-64 years)<br>From 65-84 years<br>85 years and over | 0<br>0<br>0<br>0<br>0<br>0<br>0<br>0 |  |  |
| Age continuous<br>Units: years  |                                      |  |  |
| arithmetic mean   |                                      |  |  |



|                    |   |  |  |
|--------------------|---|--|--|
| standard deviation | - |  |  |
|--------------------|---|--|--|

|                    |    |  |  |
|--------------------|----|--|--|
| Gender categorical |    |  |  |
| Units: Subjects    |    |  |  |
| Female             | 18 |  |  |
| Male               | 21 |  |  |
| PD-L1 Status       |    |  |  |
| Units: Subjects    |    |  |  |
| Positive           | 15 |  |  |
| Negative           | 21 |  |  |
| Missing            | 3  |  |  |

## End points

### End points reporting groups

|  |  |
|--|--|
| Reporting group title  | Phase 1A: BGB-A333 450 mg                        |
| Reporting group description:<br>BGB-A333 450 mg, intravenously, every 3 weeks  |  |
| Reporting group title  | Phase 1A: BGB-A333 900 mg                        |
| Reporting group description:<br>BGB-A333 900 mg, intravenously, every 3 weeks  |  |
| Reporting group title  | Phase 1A: BGB-A333 1350 mg                       |
| Reporting group description:<br>BGB-A333 1350 mg, intravenously, every 3 weeks   |  |
| Reporting group title  | Phase 1A: BGB-A333 1800 mg                       |
| Reporting group description:<br>BGB-A333 1800 mg, intravenously, every 3 weeks   |  |
| Reporting group title  | Phase 1B: BGB-A333 1350 mg + Tislelizumab 200 mg |
| Reporting group description:<br>BGB-A333 1350 mg, intravenously, + Tislelizumab 200 mg, intravenously, every 3 weeks                               |  |
| Reporting group title  | Phase 2B: BGB-A333 1350 mg + Tislelizumab 200 mg |
| Reporting group description:<br>BGB-A333 1350 mg, intravenously, + Tislelizumab 200 mg, intravenously, every 3 weeks (Urothelial Carcinoma Cohort) |  |
| Subject analysis set title   | Phase 1A: BGB-A333 Monotherapy Dose Escalation   |
| Subject analysis set type  | Safety analysis                                  |
| Subject analysis set description:<br>Dose escalation cohorts   |  |

### Primary: Phase 1 and Phase 2: Number of Subjects with Adverse Events and Serious Adverse Events

|  |   |
|--|---|
| End point title  | Phase 1 and Phase 2: Number of Subjects with Adverse Events and Serious Adverse Events <sup>[1]</sup> |
| End point description:<br>Adverse events were assessed per the National Cancer Institute Common Terminology Criteria for Adverse Events NCI-CTCAE Version 4.03 SAEs were monitored from the date of informed consent. All adverse events (AEs) and SAEs, were reported until either 30 days after the last dose of study drug or until initiation of a new anticancer therapy, whichever occurred first. |   |
| End point type   | Primary   |
| End point timeframe:<br>Up to 33.5 months  |   |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No summary statistics available for discrete values.

| End point values                            | Phase 1A: BGB-A333 450 mg | Phase 1A: BGB-A333 900 mg | Phase 1A: BGB-A333 1350 mg | Phase 1A: BGB-A333 1800 mg |
|---|---------------------------|---------------------------|----------------------------|----------------------------|
| Subject group type                          | Reporting group           | Reporting group           | Reporting group            | Reporting group            |
| Number of subjects analysed                 | 3                         | 3                         | 6                          | 3                          |
| Units: Subjects                             |                           |                           |                            |                            |
| Any Treatment Emergent Adverse Event (TEAE) | 1                         | 2                         | 6                          | 3                          |

|              |   |   |   |   |
|--------------|---|---|---|---|
| Serious TEAE | 0 | 1 | 3 | 1 |
|--------------|---|---|---|---|

|   |  |  |  |  |
|---|--|--|--|--|
| <b>End point values</b>                     | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg | Phase 2B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |
| Subject group type                          | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed                 | 12   | 12   |  |  |
| Units: Subjects                             |  |  |  |  |
| Any Treatment Emergent Adverse Event (TEAE) | 12   | 12   |  |  |
| Serious TEAE                                | 5  | 3  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Phase 1 and Phase 2: Number of Subjects with Abnormalities During Physical Examinations- Ophthalmology Findings

|                 |  |
|-----------------|--|
| End point title | Phase 1 and Phase 2: Number of Subjects with Abnormalities During Physical Examinations- Ophthalmology Findings <sup>[2]</sup> |
|-----------------|--|

End point description:

Complete physical examination including an evaluation of 1) head, eyes, ears, nose, throat, 2) cardiovascular, 3) dermatological, 4) musculoskeletal, 5) respiratory, 6) gastrointestinal, and 7) neurological systems was required to be performed at Screening. At subsequent visits (or as clinically indicated), limited, symptom-directed physical examinations were performed. Clinically significant Ophthalmology abnormalities were collected from case report forms. All AEs and SAEs, were reported until either 30 days after the last dose of study drug or until initiation of a new anticancer therapy, whichever occurred first.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 33.5 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No summary statistics available for discrete values.

|                             |                                 |                                 |                                  |                                  |
|-----------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| <b>End point values</b>     | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
| Subject group type          | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed | 3                               | 3                               | 6                                | 3                                |
| Units: Subjects             | 0                               | 0                               | 0                                | 0                                |

|                         |                                    |                                    |  |  |
|-------------------------|------------------------------------|------------------------------------|--|--|
| <b>End point values</b> | Phase 1B:<br>BGB-A333<br>1350 mg + | Phase 2B:<br>BGB-A333<br>1350 mg + |  |  |
|-------------------------|------------------------------------|------------------------------------|--|--|

|                             | Tislelizumab<br>200 mg | Tislelizumab<br>200 mg |  |  |
|-----------------------------|------------------------|------------------------|--|--|
| Subject group type          | Reporting group        | Reporting group        |  |  |
| Number of subjects analysed | 12                     | 12                     |  |  |
| Units: Subjects             | 0                      | 0                      |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Phase 1 and Phase 2: Number of Subjects with Abnormal Electrocardiograms (ECG)

|                 |   |
|-----------------|---|
| End point title | Phase 1 and Phase 2: Number of Subjects with Abnormal Electrocardiograms (ECG) <sup>[3]</sup> |
|-----------------|---|

End point description:

Central ECG data was used and the abnormality was determined by the evaluator (Investigating physician). Multiple tests such as QT, HR, PR, RR were used by the evaluator to determine abnormality. All AEs and SAEs, were reported until either 30 days after the last dose of study drug or until initiation of a new anticancer therapy, whichever occurred first.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 33.5 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No summary statistics available for discrete values.

| End point values            | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
|-----------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| Subject group type          | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed | 3                               | 3                               | 6                                | 3                                |
| Units: Subjects             | 0                               | 1                               | 5                                | 2                                |

| End point values            | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg | Phase 2B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |
|-----------------------------|--|--|--|--|
| Subject group type          | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed | 12   | 12   |  |  |
| Units: Subjects             | 1  | 9  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Phase 1 and Phase 2: Number of Subjects with Abnormal Lab Assessment Results

|                 |   |
|-----------------|---|
| End point title | Phase 1 and Phase 2: Number of Subjects with Abnormal Lab Assessment Results <sup>[4]</sup> |
|-----------------|---|

End point description:

Lab abnormality was based on ANRIND: if the measurement value > ULN (upper limit of normal), it was considered Abnormal. All AEs and SAEs, were reported until either 30 days after the last dose of study drug or until initiation of a new anticancer therapy, whichever occurred first.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 33.5 months

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No summary statistics available for discrete values

|                             |                              |                              |                               |                               |
|-----------------------------|------------------------------|------------------------------|-------------------------------|-------------------------------|
| <b>End point values</b>     | Phase 1A:<br>BGB-A333 450 mg | Phase 1A:<br>BGB-A333 900 mg | Phase 1A:<br>BGB-A333 1350 mg | Phase 1A:<br>BGB-A333 1800 mg |
| Subject group type          | Reporting group              | Reporting group              | Reporting group               | Reporting group               |
| Number of subjects analysed | 3                            | 3                            | 6                             | 3                             |
| Units: Subjects             | 3                            | 3                            | 6                             | 3                             |

|                             |  |  |  |  |
|-----------------------------|--|--|--|--|
| <b>End point values</b>     | Phase 1B:<br>BGB-A333 1350 mg +<br>Tislelizumab 200 mg | Phase 2B:<br>BGB-A333 1350 mg +<br>Tislelizumab 200 mg |  |  |
| Subject group type          | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed | 12   | 12   |  |  |
| Units: Subjects             | 12   | 12   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Phase 2B: Overall Response Rate (ORR) Determined by Investigators Based on RECIST Version 1.1

|                 |   |
|-----------------|---|
| End point title | Phase 2B: Overall Response Rate (ORR) Determined by Investigators Based on RECIST Version 1.1 <sup>[5][6]</sup> |
|-----------------|---|

End point description:

The ORR is defined as the percentage of participants who had confirmed Complete Response (CR) or Partial response (PR) assessed by investigator using RECIST version 1.1

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 33.5 months

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No summary statistics available for discrete values

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No summary statistics available for discrete values.

|                                   |  |  |  |  |
|-----------------------------------|--|--|--|--|
| <b>End point values</b>           | Phase 2B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
| Subject group type                | Reporting group  |  |  |  |
| Number of subjects analysed       | 12   |  |  |  |
| Units: Percentage of participants |  |  |  |  |
| number (confidence interval 95%)  | 41.7 (15.17 to<br>72.33)                                     |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Phase 1A: Recommended Phase 2 Dose (RP2D) for BGB-A333

|                 |  |
|-----------------|--|
| End point title | Phase 1A: Recommended Phase 2 Dose (RP2D) for BGB- |
|-----------------|--|

End point description:

RP2D for BGB-A333 alone and in combination with tislelizumab was the maximum tolerated dose (MTD) or less, which was determined by testing increasing doses up to 1800 mg.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 28 months

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No summary statistics available for discrete values

|                             |  |  |  |  |
|-----------------------------|--|--|--|--|
| <b>End point values</b>     | Phase 1A:<br>BGB-A333<br>Monotherapy<br>Dose<br>Escalation |  |  |  |
| Subject group type          | Subject analysis set                                       |  |  |  |
| Number of subjects analysed | 15   |  |  |  |
| Units: Milligrams           | 1350   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1A and Phase 1B: Overall Response Rate (ORR) Determined by

## Investigators Based on RECIST Version 1.1

|                 |  |
|-----------------|--|
| End point title | Phase 1A and Phase 1B: Overall Response Rate (ORR)<br>Determined by Investigators Based on RECIST Version 1.1 <sup>[8]</sup> |
|-----------------|--|

End point description:

ORR is defined as the percentage of participants who had confirmed CR or PR assessed by investigator using RECIST version 1.1

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 33.5 months

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification:

Not all arms in the Baseline Period are applicable for this endpoint.

| End point values                  | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
|-----------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| Subject group type                | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed       | 3                               | 3                               | 6                                | 3                                |
| Units: Percentage of participants |                                 |                                 |                                  |                                  |
| number (confidence interval 95%)  | 0.0 (0.00 to<br>70.76)          | 33.3 (0.84 to<br>90.57)         | 50.0 (11.81 to<br>88.19)         | 33.3 (0.84 to<br>90.57)          |

| End point values                  | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
|-----------------------------------|--|--|--|--|
| Subject group type                | Reporting group  |  |  |  |
| Number of subjects analysed       | 12   |  |  |  |
| Units: Percentage of participants |  |  |  |  |
| number (confidence interval 95%)  | 16.7 (2.09 to<br>48.41)                                      |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2B: Duration of Response (DOR) Determined by Investigators Based on RECIST Version 1.1

|                 |  |
|-----------------|--|
| End point title | Phase 2B: Duration of Response (DOR) Determined by<br>Investigators Based on RECIST Version 1.1 <sup>[9]</sup> |
|-----------------|--|

End point description:

DOR was defined as the time from the first determination of an objective response per RECIST version 1.1, until the first documentation of progression or death, whichever occurs first. DOR was not evaluable in Phase 1A and Phase 1B. 9999 = Data not estimable due to insufficient number of participants with events

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 33.5 months

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: No summary statistics available for discrete values.

|                                  |  |  |  |  |
|----------------------------------|--|--|--|--|
| <b>End point values</b>          | Phase 2B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
| Subject group type               | Reporting group  |  |  |  |
| Number of subjects analysed      | 12   |  |  |  |
| Units: Months                    |  |  |  |  |
| median (confidence interval 95%) | 9.6 (6.0 to<br>9999)   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1 and Phase 2: Disease Control Rate (DCR) Determined by Investigators Based on RECIST Version 1.1

|                 |   |
|-----------------|---|
| End point title | Phase 1 and Phase 2: Disease Control Rate (DCR) Determined by Investigators Based on RECIST Version 1.1 |
|-----------------|---|

End point description:

DCR is defined as the proportion of participants with best overall response of CR, PR and Stable Disease.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 33.5 months

|                                  |                                 |                                 |                                  |                                  |
|----------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| <b>End point values</b>          | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
| Subject group type               | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed      | 3                               | 3                               | 6                                | 3                                |
| Units: Percentage of subjects    |                                 |                                 |                                  |                                  |
| number (confidence interval 95%) | 33.3 (0.84 to<br>90.57)         | 33.3 (0.84 to<br>90.57)         | 66.7 (22.28 to<br>95.67)         | 66.7 (9.43 to<br>99.16)          |

|                         |  |  |  |  |
|-------------------------|--|--|--|--|
| <b>End point values</b> | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg | Phase 2B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |
|-------------------------|--|--|--|--|



|                                  |                       |                       |  |  |
|----------------------------------|-----------------------|-----------------------|--|--|
| Subject group type               | Reporting group       | Reporting group       |  |  |
| Number of subjects analysed      | 12                    | 12                    |  |  |
| Units: Percentage of subjects    |                       |                       |  |  |
| number (confidence interval 95%) | 58.3 (27.67 to 84.83) | 75.0 (42.81 to 94.51) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2B: Progression-free Survival (PFS) Determined by Investigators Based on RECIST Version 1.1

|                 |   |
|-----------------|---|
| End point title | Phase 2B: Progression-free Survival (PFS) Determined by Investigators Based on RECIST Version 1.1 <sup>[10]</sup> |
|-----------------|---|

End point description:

PFS was defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of disease progression assessed by investigator using RECIST v1.1 or death, whichever occurs first

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 33.5 months

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Not all arms in the Baseline Period are applicable for this endpoint

|                                  |  |  |  |  |
|----------------------------------|--|--|--|--|
| <b>End point values</b>          | Phase 2B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
| Subject group type               | Reporting group  |  |  |  |
| Number of subjects analysed      | 12   |  |  |  |
| Units: Months                    |  |  |  |  |
| median (confidence interval 95%) | 6.1 (1.9 to 11.0)  |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Maximum Plasma Concentration (Cmax) of BGB-A333

|                 |  |
|-----------------|--|
| End point title | Phase 1: Maximum Plasma Concentration (Cmax) of BGB- |
|-----------------|--|

End point description:

PK parameters were derived only for Phase 1A and Phase 1B. Phase 2B PK parameters were not estimated due to limited sampling. Actual observed time values for PK sampling, have an allowable time deviation (+/- 3 days) from the planned nominal time as pre-specified in the Visit Window section of the study protocol.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1 (Pre-dose, End of infusion, 6 hours), Day 2, Day 4, Day 8, Day 15 and Day 21

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Not all arms in the Baseline Period are applicable for this endpoint.

| End point values                     | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
|--------------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| Subject group type                   | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed          | 3                               | 3                               | 6                                | 3                                |
| Units: ug/mL                         |                                 |                                 |                                  |                                  |
| arithmetic mean (standard deviation) | 167 (± 42.4)                    | 351 (± 151)                     | 466 (± 91.0)                     | 594 (± 150)                      |

| End point values                     | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
|--------------------------------------|--|--|--|--|
| Subject group type                   | Reporting group  |  |  |  |
| Number of subjects analysed          | 12   |  |  |  |
| Units: ug/mL                         |  |  |  |  |
| arithmetic mean (standard deviation) | 450 (± 127)  |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Time to Cmax (Tmax) of BGB-A333

|                 |  |
|-----------------|--|
| End point title | Phase 1: Time to Cmax (Tmax) of BGB-A333 <sup>[12]</sup> |
|-----------------|--|

End point description:

PK parameters were derived only for Phase 1A and Phase 1B. Phase 2B PK parameters were not estimated due to limited sampling.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1 (Pre-dose, End of infusion, 6 hours), Day 2, Day 4, Day 8, Day 15 and Day 21

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Not all arms in the Baseline Period are applicable for this endpoint.

| End point values              | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
|-------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| Subject group type            | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed   | 3                               | 3                               | 6                                | 3                                |
| Units: Day                    |                                 |                                 |                                  |                                  |
| median (full range (min-max)) | 0.05 (0.04 to<br>0.21)          | 0.06 (0.05 to<br>0.06)          | 0.05 (0.05 to<br>0.22)           | 0.06 (0.06 to<br>0.21)           |

| End point values              | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  |  |  |  |
| Number of subjects analysed   | 12   |  |  |  |
| Units: Day                    |  |  |  |  |
| median (full range (min-max)) | 0.21 (0.05 to<br>0.22)                                       |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Trough Serum Concentration (C<sub>trough</sub>) of BGB-A333

|                 |  |
|-----------------|--|
| End point title | Phase 1: Trough Serum Concentration (C <sub>trough</sub> ) of BGB- |
|-----------------|--|

End point description:

PK parameters were derived only for Phase 1A and Phase 1B. Phase 2B PK parameters were not estimated due to limited sampling.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1 (Pre-dose, End of infusion, 6 hours), Day 2, Day 4, Day 8, Day 15 and Day 21

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Not all arms in the Baseline Period are applicable for this endpoint

| End point values                     | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
|--------------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| Subject group type                   | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed          | 3                               | 3                               | 6                                | 3                                |
| Units: ug/mL                         |                                 |                                 |                                  |                                  |
| arithmetic mean (standard deviation) | 21.3 (± 5.69)                   | 47.0 (± 26.7)                   | 90.7 (± 24.2)                    | 81.4 (± 23.9)                    |

| End point values | Phase 1B:<br>BGB-A333 |  |  |  |
|------------------|-----------------------|--|--|--|
|------------------|-----------------------|--|--|--|

|                                      |                                     |  |  |  |
|--------------------------------------|-------------------------------------|--|--|--|
|                                      | 1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
| Subject group type                   | Reporting group                     |  |  |  |
| Number of subjects analysed          | 12                                  |  |  |  |
| Units: ug/mL                         |                                     |  |  |  |
| arithmetic mean (standard deviation) | 80.0 (± 22.0)                       |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Time to Last Observed Concentration (Tlast) of BGB-A333

|                 |  |
|-----------------|--|
| End point title | Phase 1: Time to Last Observed Concentration (Tlast) of BGB-A333 <sup>[14]</sup> |
|-----------------|--|

End point description:

PK parameters were derived only for Phase 1A and Phase 1B. Phase 2B PK parameters were not estimated due to limited sampling.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1 (Pre-dose, End of infusion, 6 hours), Day 2, Day 4, Day 8, Day 15 and Day 21

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Not all arms in the Baseline Period are applicable for this endpoint

| End point values              | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
|-------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| Subject group type            | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed   | 3                               | 3                               | 6                                | 3                                |
| Units: Day                    |                                 |                                 |                                  |                                  |
| median (full range (min-max)) | 22.0 (21.0 to<br>22.0)          | 21.0 (14.1 to<br>21.0)          | 21.0 (14.0 to<br>22.0)           | 21.0 (21.0 to<br>24.0)           |

| End point values              | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  |  |  |  |
| Number of subjects analysed   | 12   |  |  |  |
| Units: Day                    |  |  |  |  |
| median (full range (min-max)) | 21.0 (7.10 to<br>24.0)                                       |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1: Area Under the Concentration-time Curve From 9 to 21 Days Post-dose (AUC0-21day) of BGB-A333

|                 |   |
|-----------------|---|
| End point title | Phase 1: Area Under the Concentration-time Curve From 9 to 21 Days Post-dose (AUC0-21day) of BGB-A333 <sup>[15]</sup> |
|-----------------|---|

End point description:

PK parameters were derived only for Phase 1A and Phase 1B. Phase 2B PK parameters were not estimated due to limited sampling.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Cycle 1 Day 1 (Pre-dose, End of infusion, 6 hours), Day 2, Day 4, Day 8, Day 15 and Day 21

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Not all arms in the Baseline Period are applicable for this endpoint

| End point values                     | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
|--------------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| Subject group type                   | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed          | 3                               | 2                               | 5                                | 3                                |
| Units: ug*day/mL                     |                                 |                                 |                                  |                                  |
| arithmetic mean (standard deviation) | 1095 (± 141)                    | 2913 (± 320)                    | 3823 (± 566)                     | 4141 (± 648)                     |

| End point values                     | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |  |
|--------------------------------------|--|--|--|--|
| Subject group type                   | Reporting group  |  |  |  |
| Number of subjects analysed          | 11   |  |  |  |
| Units: ug*day/mL                     |  |  |  |  |
| arithmetic mean (standard deviation) | 3546 (± 814)   |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 1A and Phase 2: Number of Subjects with Detectable Treatment-emergent Anti-BGB-A333 Antibodies

|                 |  |
|-----------------|--|
| End point title | Phase 1A and Phase 2: Number of Subjects with Detectable Treatment-emergent Anti-BGB-A333 Antibodies |
|-----------------|--|

End point description:

Treatment-emergent anti drug antibodies (ADA) was the sum of both treatment-induced ADA and treatment-boosted ADA, synonymous with "ADA incidence"

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 33.5 months

| <b>End point values</b>     | Phase 1A:<br>BGB-A333 450<br>mg | Phase 1A:<br>BGB-A333 900<br>mg | Phase 1A:<br>BGB-A333<br>1350 mg | Phase 1A:<br>BGB-A333<br>1800 mg |
|-----------------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|
| Subject group type          | Reporting group                 | Reporting group                 | Reporting group                  | Reporting group                  |
| Number of subjects analysed | 3                               | 3                               | 6                                | 3                                |
| Units: Subjects             | 1                               | 1                               | 1                                | 0                                |

| <b>End point values</b>     | Phase 1B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg | Phase 2B:<br>BGB-A333<br>1350 mg +<br>Tislelizumab<br>200 mg |  |  |
|-----------------------------|--|--|--|--|
| Subject group type          | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed | 11   | 12   |  |  |
| Units: Subjects             | 0  | 4  |  |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From the date of consent until study termination (approximately 33.5 months)

Adverse event reporting additional description:

All adverse events were reported until either 30 days after the last dose of study drug or until initiation of a new anticancer therapy, whichever occurred first.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 23.0 |
|--------------------|------|

### Reporting groups

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | Phase 1A: BGB-A333 450 mg |
|-----------------------|---------------------------|

Reporting group description:

BGB-333 450 mg, intravenously, every 3 weeks

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | Phase 1A: BGB-A333 900 mg |
|-----------------------|---------------------------|

Reporting group description:

BGB-333 900 mg, intravenously, every 3 weeks

|                       |                            |
|-----------------------|----------------------------|
| Reporting group title | Phase 1A: BGB-A333 1350 mg |
|-----------------------|----------------------------|

Reporting group description:

BGB-333 1350 mg, intravenously, every 3 weeks

|                       |                            |
|-----------------------|----------------------------|
| Reporting group title | Phase 1A: BGB-A333 1800 mg |
|-----------------------|----------------------------|

Reporting group description:

BGB-333 1800 mg, intravenously, every 3 weeks

|                       |  |
|-----------------------|--|
| Reporting group title | Phase 1B: BGB-A333 1350 mg + Tislelizumab 200 mg |
|-----------------------|--|

Reporting group description:

BGB-333 1350 mg, intravenously, + Tislelizumab 200 mg, intravenously, every 3 weeks

|                       |  |
|-----------------------|--|
| Reporting group title | Phase 2B: BGB-A333 1350 mg + Tislelizumab 200 mg |
|-----------------------|--|

Reporting group description:

BGB-333 1350 mg, intravenously, + Tislelizumab 200 mg, intravenously, every 3 weeks (Urothelial Carcinoma Cohort)

| Serious adverse events  | Phase 1A: BGB-A333 450 mg | Phase 1A: BGB-A333 900 mg | Phase 1A: BGB-A333 1350 mg |
|---|---------------------------|---------------------------|----------------------------|
| Total subjects affected by serious adverse events                   |                           |                           |                            |
| subjects affected / exposed   | 0 / 3 (0.00%)             | 1 / 3 (33.33%)            | 3 / 6 (50.00%)             |
| number of deaths (all causes)                                       | 0                         | 1                         | 2                          |
| number of deaths resulting from adverse events                      | 0                         | 0                         | 0                          |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                           |                           |                            |
| Tumour haemorrhage  |                           |                           |                            |
| subjects affected / exposed   | 0 / 3 (0.00%)             | 1 / 3 (33.33%)            | 0 / 6 (0.00%)              |
| occurrences causally related to treatment / all                     | 0 / 0                     | 0 / 1                     | 0 / 0                      |
| deaths causally related to treatment / all                          | 0 / 0                     | 0 / 0                     | 0 / 0                      |

|  |               |               |                |
|--|---------------|---------------|----------------|
| Cardiac disorders                                    |               |               |                |
| Supraventricular tachycardia                         |               |               |                |
| subjects affected / exposed                          | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Nervous system disorders                             |               |               |                |
| Spinal cord compression                              |               |               |                |
| subjects affected / exposed                          | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| General disorders and administration site conditions |               |               |                |
| Generalised oedema                                   |               |               |                |
| subjects affected / exposed                          | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Multiple organ dysfunction syndrome                  |               |               |                |
| subjects affected / exposed                          | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Gastrointestinal disorders                           |               |               |                |
| Dysphagia  |               |               |                |
| subjects affected / exposed                          | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Small intestinal obstruction                         |               |               |                |
| subjects affected / exposed                          | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 6 (16.67%) |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders      |               |               |                |
| Pneumonia aspiration                                 |               |               |                |
| subjects affected / exposed                          | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0         | 0 / 0         | 0 / 0          |
| Pleural effusion                                     |               |               |                |



|   |               |               |                |
|---|---------------|---------------|----------------|
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Hepatobiliary disorders                         |               |               |                |
| Immune-mediated hepatitis                       |               |               |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Renal and urinary disorders                     |               |               |                |
| Acute kidney injury                             |               |               |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Haematuria                                      |               |               |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Endocrine disorders                             |               |               |                |
| Hypophysitis                                    |               |               |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Musculoskeletal and connective tissue disorders |               |               |                |
| Back pain                                       |               |               |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Infections and infestations                     |               |               |                |
| Respiratory tract infection                     |               |               |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 6 (16.67%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Vestibular neuronitis                           |               |               |                |

|   |               |               |                |
|---|---------------|---------------|----------------|
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 6 (16.67%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |
| Parainfluenzae virus infection                  |               |               |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 6 (0.00%)  |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0         | 0 / 0          |

| <b>Serious adverse events</b>                                       | Phase 1A: BGB-A333 1800 mg | Phase 1B: BGB-A333 1350 mg + Tislelizumab 200 mg | Phase 2B: BGB-A333 1350 mg + Tislelizumab 200 mg |
|---|----------------------------|--|--|
| Total subjects affected by serious adverse events                   |                            |  |  |
| subjects affected / exposed   | 1 / 3 (33.33%)             | 5 / 12 (41.67%)                                  | 3 / 12 (25.00%)                                  |
| number of deaths (all causes)                                       | 1                          | 4  | 2  |
| number of deaths resulting from adverse events                      | 0                          | 0  | 0  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                            |  |  |
| Tumour haemorrhage  |                            |  |  |
| subjects affected / exposed   | 0 / 3 (0.00%)              | 1 / 12 (8.33%)                                   | 0 / 12 (0.00%)                                   |
| occurrences causally related to treatment / all                     | 0 / 0                      | 0 / 1  | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0                      | 0 / 0  | 0 / 0  |
| Cardiac disorders   |                            |  |  |
| Supraventricular tachycardia  |                            |  |  |
| subjects affected / exposed   | 0 / 3 (0.00%)              | 1 / 12 (8.33%)                                   | 0 / 12 (0.00%)                                   |
| occurrences causally related to treatment / all                     | 0 / 0                      | 0 / 1  | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0                      | 0 / 0  | 0 / 0  |
| Nervous system disorders  |                            |  |  |
| Spinal cord compression   |                            |  |  |
| subjects affected / exposed   | 0 / 3 (0.00%)              | 1 / 12 (8.33%)                                   | 0 / 12 (0.00%)                                   |
| occurrences causally related to treatment / all                     | 0 / 0                      | 0 / 1  | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0                      | 0 / 0  | 0 / 0  |
| General disorders and administration site conditions                |                            |  |  |
| Generalised oedema  |                            |  |  |
| subjects affected / exposed   | 0 / 3 (0.00%)              | 0 / 12 (0.00%)                                   | 1 / 12 (8.33%)                                   |
| occurrences causally related to treatment / all                     | 0 / 0                      | 0 / 0  | 0 / 1  |
| deaths causally related to treatment / all                          | 0 / 0                      | 0 / 0  | 0 / 0  |
| Multiple organ dysfunction syndrome                                 |                            |  |  |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 3 (0.00%)  | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Dysphagia                                       |                |                |                |
| subjects affected / exposed                     | 1 / 3 (33.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Small intestinal obstruction                    |                |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%)  | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| Pneumonia aspiration                            |                |                |                |
| subjects affected / exposed                     | 1 / 3 (33.33%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pleural effusion                                |                |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%)  | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                |                |                |
| Immune-mediated hepatitis                       |                |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%)  | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Renal and urinary disorders                     |                |                |                |
| Acute kidney injury                             |                |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%)  | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Haematuria                                      |                |                |                |

|   |               |                |                |
|---|---------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0          |
| Endocrine disorders                             |               |                |                |
| Hypophysitis                                    |               |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |               |                |                |
| Back pain                                       |               |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 12 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0          |
| Infections and infestations                     |               |                |                |
| Respiratory tract infection                     |               |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0          |
| Vestibular neuronitis                           |               |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 0 / 12 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0          |
| Parainfluenzae virus infection                  |               |                |                |
| subjects affected / exposed                     | 0 / 3 (0.00%) | 1 / 12 (8.33%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0         | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0         | 0 / 0          | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 3 %

| Non-serious adverse events                            | Phase 1A: BGB-A333 450 mg | Phase 1A: BGB-A333 900 mg | Phase 1A: BGB-A333 1350 mg |
|---|---------------------------|---------------------------|----------------------------|
| Total subjects affected by non-serious adverse events |                           |                           |                            |
| subjects affected / exposed                           | 1 / 3 (33.33%)            | 2 / 3 (66.67%)            | 6 / 6 (100.00%)            |
| General disorders and administration site conditions  |                           |                           |                            |

|  |                     |                     |                     |
|--|---------------------|---------------------|---------------------|
| Fatigue<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 1 / 6 (16.67%)<br>1 |
| Asthenia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0  |
| Reproductive system and breast disorders<br>Pelvic pain<br>subjects affected / exposed<br>occurrences (all)  | 1 / 3 (33.33%)<br>1 | 0 / 3 (0.00%)<br>0  | 1 / 6 (16.67%)<br>1 |
| Perineal pain<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Respiratory, thoracic and mediastinal disorders<br>Cough<br>subjects affected / exposed<br>occurrences (all) | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0  |
| Psychiatric disorders<br>Insomnia<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Investigations<br>Blood creatinine increased<br>subjects affected / exposed<br>occurrences (all)             | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 1 / 6 (16.67%)<br>1 |
| Nervous system disorders<br>Headache<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0  |
| Paraesthesia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Presyncope   |                     |                     |                     |

|   |                     |                     |                     |
|---|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 1 / 6 (16.67%)<br>1 |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)               | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0  |
| Eye disorders<br>Cataract<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Gastrointestinal disorders<br>Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 1 / 6 (16.67%)<br>1 |
| Nausea<br>subjects affected / exposed<br>occurrences (all)  | 1 / 3 (33.33%)<br>1 | 0 / 3 (0.00%)<br>0  | 3 / 6 (50.00%)<br>4 |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 3 / 6 (50.00%)<br>3 |
| Abdominal pain upper<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 1 / 6 (16.67%)<br>1 |
| Constipation<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0  |
| Skin and subcutaneous tissue disorders<br>Rash maculo-papular<br>subjects affected / exposed<br>occurrences (all) | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0  |
| Pruritus<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Rash<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0  |
| Renal and urinary disorders   |                     |                     |                     |

|   |                    |                     |                     |
|---|--------------------|---------------------|---------------------|
| Proteinuria<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Musculoskeletal and connective tissue disorders                                       |                    |                     |                     |
| Myalgia<br>subjects affected / exposed<br>occurrences (all)                           | 0 / 3 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0  |
| Musculoskeletal chest pain<br>subjects affected / exposed<br>occurrences (all)        | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 3 (0.00%)<br>0 | 1 / 3 (33.33%)<br>5 | 0 / 6 (0.00%)<br>0  |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Muscle spasms<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Musculoskeletal pain<br>subjects affected / exposed<br>occurrences (all)              | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Infections and infestations   |                    |                     |                     |
| Lower respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 2 / 6 (33.33%)<br>2 |
| Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)           | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0  |
| Oral candidiasis<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 1 / 6 (16.67%)<br>2 |
| Metabolism and nutrition disorders  |                    |                     |                     |

|   |                    |                     |                    |
|---|--------------------|---------------------|--------------------|
| Hypophosphataemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0 |
| Hypercalcaemia<br>subjects affected / exposed<br>occurrences (all)    | 0 / 3 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 0 / 6 (0.00%)<br>0 |
| Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all)    | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0 |
| Hyperkalaemia<br>subjects affected / exposed<br>occurrences (all)     | 0 / 3 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 6 (0.00%)<br>0 |

| <b>Non-serious adverse events</b>  | Phase 1A: BGB-A333 1800 mg | Phase 1B: BGB-A333 1350 mg + Tislelizumab 200 mg | Phase 2B: BGB-A333 1350 mg + Tislelizumab 200 mg |
|--|----------------------------|--|--|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed | 3 / 3 (100.00%)            | 12 / 12 (100.00%)                                | 12 / 12 (100.00%)                                |
| General disorders and administration site conditions                                 |                            |  |  |
| Fatigue<br>subjects affected / exposed<br>occurrences (all)                          | 2 / 3 (66.67%)<br>2        | 2 / 12 (16.67%)<br>3                             | 2 / 12 (16.67%)<br>2                             |
| Asthenia<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 3 (0.00%)<br>0         | 0 / 12 (0.00%)<br>0                              | 3 / 12 (25.00%)<br>3                             |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)                          | 1 / 3 (33.33%)<br>1        | 1 / 12 (8.33%)<br>1                              | 0 / 12 (0.00%)<br>0                              |
| Reproductive system and breast disorders   |                            |  |  |
| Pelvic pain<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 3 (0.00%)<br>0         | 0 / 12 (0.00%)<br>0                              | 0 / 12 (0.00%)<br>0                              |
| Perineal pain<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 3 (0.00%)<br>0         | 2 / 12 (16.67%)<br>4                             | 0 / 12 (0.00%)<br>0                              |
| Respiratory, thoracic and mediastinal disorders                                      |                            |  |  |



|  |  |   |   |
|--|--|---|---|
| Cough<br>subjects affected / exposed<br>occurrences (all)  | 1 / 3 (33.33%)<br>1  | 3 / 12 (25.00%)<br>3  | 0 / 12 (0.00%)<br>0   |
| Psychiatric disorders<br>Insomnia<br>subjects affected / exposed<br>occurrences (all)  | 1 / 3 (33.33%)<br>1  | 1 / 12 (8.33%)<br>1   | 2 / 12 (16.67%)<br>2  |
| Investigations<br>Blood creatinine increased<br>subjects affected / exposed<br>occurrences (all)   | 0 / 3 (0.00%)<br>0   | 0 / 12 (0.00%)<br>0   | 2 / 12 (16.67%)<br>2  |
| Nervous system disorders<br>Headache<br>subjects affected / exposed<br>occurrences (all)<br><br>Paraesthesia<br>subjects affected / exposed<br>occurrences (all)<br><br>Presyncope<br>subjects affected / exposed<br>occurrences (all) | 1 / 3 (33.33%)<br>2<br><br>1 / 3 (33.33%)<br>1<br><br>0 / 3 (0.00%)<br>0 | 0 / 12 (0.00%)<br>0<br><br>1 / 12 (8.33%)<br>1<br><br>1 / 12 (8.33%)<br>1 | 1 / 12 (8.33%)<br>1<br><br>0 / 12 (0.00%)<br>0<br><br>0 / 12 (0.00%)<br>0 |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)  | 1 / 3 (33.33%)<br>1  | 3 / 12 (25.00%)<br>4  | 1 / 12 (8.33%)<br>2   |
| Eye disorders<br>Cataract<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0   | 1 / 12 (8.33%)<br>1   | 1 / 12 (8.33%)<br>1   |
| Gastrointestinal disorders<br>Diarrhoea<br>subjects affected / exposed<br>occurrences (all)<br><br>Nausea<br>subjects affected / exposed<br>occurrences (all)<br><br>Vomiting  | 1 / 3 (33.33%)<br>1<br><br>0 / 3 (0.00%)<br>0                            | 4 / 12 (33.33%)<br>4<br><br>4 / 12 (33.33%)<br>4                          | 2 / 12 (16.67%)<br>4<br><br>0 / 12 (0.00%)<br>0                           |

|   |                     |                      |                      |
|---|---------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 1 / 12 (8.33%)<br>1  | 1 / 12 (8.33%)<br>1  |
| Abdominal pain upper<br>subjects affected / exposed<br>occurrences (all)  | 1 / 3 (33.33%)<br>1 | 0 / 12 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  |
| Constipation<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 1 / 12 (8.33%)<br>1  | 0 / 12 (0.00%)<br>0  |
| Skin and subcutaneous tissue disorders<br>Rash maculo-papular<br>subjects affected / exposed<br>occurrences (all) | 1 / 3 (33.33%)<br>1 | 2 / 12 (16.67%)<br>9 | 1 / 12 (8.33%)<br>1  |
| Pruritus<br>subjects affected / exposed<br>occurrences (all)  | 1 / 3 (33.33%)<br>1 | 2 / 12 (16.67%)<br>2 | 1 / 12 (8.33%)<br>1  |
| Rash<br>subjects affected / exposed<br>occurrences (all)  | 1 / 3 (33.33%)<br>5 | 0 / 12 (0.00%)<br>0  | 1 / 12 (8.33%)<br>1  |
| Renal and urinary disorders<br>Proteinuria<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 3 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 2 / 12 (16.67%)<br>2 |
| Musculoskeletal and connective tissue disorders<br>Myalgia<br>subjects affected / exposed<br>occurrences (all)    | 2 / 3 (66.67%)<br>2 | 1 / 12 (8.33%)<br>1  | 1 / 12 (8.33%)<br>1  |
| Musculoskeletal chest pain<br>subjects affected / exposed<br>occurrences (all)                                    | 1 / 3 (33.33%)<br>1 | 2 / 12 (16.67%)<br>2 | 1 / 12 (8.33%)<br>1  |
| Pain in extremity<br>subjects affected / exposed<br>occurrences (all)   | 0 / 3 (0.00%)<br>0  | 2 / 12 (16.67%)<br>2 | 2 / 12 (16.67%)<br>2 |
| Back pain<br>subjects affected / exposed<br>occurrences (all)   | 1 / 3 (33.33%)<br>1 | 0 / 12 (0.00%)<br>0  | 1 / 12 (8.33%)<br>3  |
| Arthralgia  |                     |                      |                      |

|  |                     |                      |                      |
|--|---------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)   | 1 / 3 (33.33%)<br>1 | 1 / 12 (8.33%)<br>7  | 0 / 12 (0.00%)<br>0  |
| Muscle spasms<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 2 / 12 (16.67%)<br>2 | 0 / 12 (0.00%)<br>0  |
| Musculoskeletal pain<br>subjects affected / exposed<br>occurrences (all)   | 1 / 3 (33.33%)<br>1 | 1 / 12 (8.33%)<br>2  | 0 / 12 (0.00%)<br>0  |
| Infections and infestations<br>Lower respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 3 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 1 / 12 (8.33%)<br>2  |
| Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  | 2 / 12 (16.67%)<br>2 |
| Oral candidiasis<br>subjects affected / exposed<br>occurrences (all)   | 1 / 3 (33.33%)<br>1 | 0 / 12 (0.00%)<br>0  | 1 / 12 (8.33%)<br>1  |
| Metabolism and nutrition disorders<br>Hypophosphataemia<br>subjects affected / exposed<br>occurrences (all)          | 1 / 3 (33.33%)<br>1 | 1 / 12 (8.33%)<br>1  | 1 / 12 (8.33%)<br>1  |
| Hypercalcaemia<br>subjects affected / exposed<br>occurrences (all)   | 1 / 3 (33.33%)<br>1 | 0 / 12 (0.00%)<br>0  | 0 / 12 (0.00%)<br>0  |
| Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all)   | 1 / 3 (33.33%)<br>1 | 1 / 12 (8.33%)<br>1  | 0 / 12 (0.00%)<br>0  |
| Hyperkalaemia<br>subjects affected / exposed<br>occurrences (all)  | 0 / 3 (0.00%)<br>0  | 1 / 12 (8.33%)<br>1  | 1 / 12 (8.33%)<br>1  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date         | Amendment  |
|--------------|--|
| 12 June 2018 | <ul style="list-style-type: none"><li>• BGB-A317 was replaced with its generic name tislelizumab.</li><li>• The study design was revised so that for Phase 2A and Phase 2B, approximately 20 patients with UC were to be enrolled. The sponsor may have considered other tumor types including but not limited to non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, gastric cancer, MSI-high cancer, etc. Eligibility criteria for these cohorts was to be defined in future protocol amendments based on emerging clinical data. Sample size for Phase 2A and Phase 2B was adjusted.</li><li>• The safety follow-up period was modified to include telephone contacts at Day 60 and Day 90 to assess immune-mediated AEs and concomitant medications, regardless of whether or not the patient started a new anticancer therapy.</li><li>• The survival follow-up period was removed.</li><li>• A requirement of antiviral therapy in patients with active hepatitis B was added, as was viral load testing.</li><li>• Restrictions of hepatotoxic drugs, alcohol, and addictive drugs in patients with hepatocellular carcinoma were added.</li><li>• Eye examinations were added.</li><li>• The inclusion and exclusion criteria were revised.</li></ul> <p>Patients who had detectable hepatitis B virus DNA at screening were to have the viral load test performed every 4 cycles, at the end of treatment visit, and when clinically indicated.</p> <ul style="list-style-type: none"><li>• Tumor and response evaluations were revised so that tumor response would be assessed by the investigators using RECIST v1.1, and additional information on new lesions was collected according to iRECIST. The sponsor was to derive tumor response using iRECIST as an exploratory assessment. Imaging of the brain at screening was required for all patients.</li><li>• The documentation method for SAE reporting was modified.</li><li>• Creatine kinase and creatine kinase-MB tests were added.</li><li>• The American Society of Clinical Oncology guideline and regulatory feedback on other studies of tislelizumab was added.</li><li>• Child-Pugh classification was added.</li></ul> |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date              | Interruption  | Restart date |
|-------------------|---|--------------|
| 08 September 2020 | The sponsor decided not to pursue BGB-A333 as a monotherapy beyond the completion of dose escalation in Phase 1A. As such, Phase 2A was not conducted. Phase 1B was opened for dose expansion and enrolled 12 patients. For Phase 2B, only 1 cohort was opened for dose expansion and a total of 12 patients were treated in the metastatic UC arm. The sponsor terminated the study after Protocol Amendment 1 since the primary objective of assessing objective response rate (ORR) had been achieved. | -            |

---

Notes:

## **Limitations and caveats**

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

|   |
|---|
| Phase 2A of the study was not initiated nor conducted since BGB-A333 as a monotherapy treatment beyond the completion of dose escalation in Phase 1A was not pursued. |
|---|

Notes: